Elixir Pharmaceuticals, a developer of metabolic disease drugs, has completed a $12 million equity financing led by MPM Capital, via MPM Bio IV NVS Strategic Fund. Additional investors in the round ...
Elixir Pharmaceuticals' Phase III Trial of Metformin-Mitiglinide Combination Therapy Demonstrates Significant Reductions in HbA1c (Blood Glucose) Levels Compared to Type 2 Diabetes Patients Not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results